A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR)Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM
Grant Data
Project Title
A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR)Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM
Principal Investigator
Dr Ho, James Chung Man
(Principal Investigator (PI))
Co-Investigator(s)
Dr Wong Matthew
(Co-Investigator)
Dr Lam Chi Leung David
(Co-Investigator)
Dr Lam Jamie
(Co-Investigator)
Duration
36
Start Date
2012-02-01
Amount
207773
Conference Title
A Phase III Randomised, Double blind, Placebo controlled, Parallel, Multicentre Study to Assess the Efficacy and Safety of continuing IRESSATM 250 mg in addition to Chemotherapy versus Chemotherapy alone in Patients who have Epidermal Growth Factor Receptor (EGFR)Mutation Positive Locally advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and have progressed on First Line IRESSATM
Presentation Title
Keywords
Non-small cell lung cancer
Discipline
Cancer
HKU Project Code
N/A
Grant Type
Pharmaceutical Industry - General Award
Funding Year
2011
Status
On-going